Athira Pharma, a Phase 2/3 biotech targeting the novel HGF/MET pathway for Alzheimer's, raised $204 million by offering 12 million shares at $17, the high end of the range of $15 to $17. The company offered 2 million more shares than anticipated. At pricing, the company raised 28% more in proceeds than expected.
Athira Pharma plans to list on the Nasdaq under the symbol ATHA. Goldman Sachs, Jefferies and Stifel acted as lead managers on the deal.
The article Neurodegeneration biotech Athira Pharma prices upsized IPO at $17 high end originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.